Fountain SynNad+ (Australia Lockey Biotechnology Pty Ltd)
Product Name
Fountain SynNad+
ARTG details
325407
Date of review outcome
Date cancellation takes effect
Date of publication
Sep-2026
Outcome
Medicine is no longer permitted to be supplied
Is it safe to continue using this medicine?
Yes, based on the sponsor's certification. However, use of this medicine may pose a safety risk for some people. Follow the recommended actions below.
What action should consumers take?
In very rare cases, Curcuma species may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine, or itching.
Do not take while on warfarin therapy without medical advice.
If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use.
Do not exceed a maximum dose of 1 tablet per day.
Seek advice from a doctor if you have been using this medicine to prevent or treat cerebral thrombosis, bowel cancer, age-related diseases, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, cardiovascular disease, or eczema.
Seek advice from a health professional if you experience itchy skin, flushing, tingling, redness, and irritation when taking this medicine as these can be symptoms of allergic or anaphylactic reactions.
Consider whether this medicine is right for you based on this medicine potentially not working as expected in relation to boosting NAD+, increasing NAD+ levels, NAD+ metabolism, maintaining NAD+ levels, raising NAD+ levels in the hypothalamus, improving cellular regeneration, activating neurotransmitters to enhance sense of well-being, removing senescent cells, anti-aging, slowing down the aging process, relieving chronic inflammation, relieving symptoms of arthritis/osteoarthritis, increasing energy expenditure, promoting brain function, or protecting the brain from oxidative stress.
Be aware this medicine does not contain the ingredient NAD as implied by its name.
Do not take while on warfarin therapy without medical advice.
If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use.
Do not exceed a maximum dose of 1 tablet per day.
Seek advice from a doctor if you have been using this medicine to prevent or treat cerebral thrombosis, bowel cancer, age-related diseases, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, cardiovascular disease, or eczema.
Seek advice from a health professional if you experience itchy skin, flushing, tingling, redness, and irritation when taking this medicine as these can be symptoms of allergic or anaphylactic reactions.
Consider whether this medicine is right for you based on this medicine potentially not working as expected in relation to boosting NAD+, increasing NAD+ levels, NAD+ metabolism, maintaining NAD+ levels, raising NAD+ levels in the hypothalamus, improving cellular regeneration, activating neurotransmitters to enhance sense of well-being, removing senescent cells, anti-aging, slowing down the aging process, relieving chronic inflammation, relieving symptoms of arthritis/osteoarthritis, increasing energy expenditure, promoting brain function, or protecting the brain from oxidative stress.
Be aware this medicine does not contain the ingredient NAD as implied by its name.
Review scope
Targeted (see Additional Information below)
Information reviewed
ARTG Record, Labels, Manufacturing Documentation, Website
Issues related to safety
The labels and website for this medicine contained statements and claims outlined in 'What action should consumers take?'. These statements and claims are not permitted for listed medicines without prior evaluation or approval from the TGA. References to non-permitted claims and promoting ignoring potential side-effects have the potential to lead consumers to delay access to timely advice or treatment from a suitably qualified health professional, which may result in adverse outcomes.
The labels for this medicine were missing the mandatory warning statements for Curcuma longa, ubidecarenone, and nicotinic acid outlined in 'What actions should consumers take?'. These warning statements are necessary to ensure the safe use of this medicine and to alert consumers to safety risks prior to taking it.
This medicine contains an amount of folic acid that exceeds the permitted limit for listed medicines at the labelled maximum daily dose (2 tablets). Ingredient limits for listed medicines are in place to ensure their safety.
While these issues are unacceptable, supply of the medicine ceased in February 2026, the sponsor removed the advertisements for this medicine, and current data indicates it is unlikely to pose an immediate risk to consumer health and safety.
The labels for this medicine were missing the mandatory warning statements for Curcuma longa, ubidecarenone, and nicotinic acid outlined in 'What actions should consumers take?'. These warning statements are necessary to ensure the safe use of this medicine and to alert consumers to safety risks prior to taking it.
This medicine contains an amount of folic acid that exceeds the permitted limit for listed medicines at the labelled maximum daily dose (2 tablets). Ingredient limits for listed medicines are in place to ensure their safety.
While these issues are unacceptable, supply of the medicine ceased in February 2026, the sponsor removed the advertisements for this medicine, and current data indicates it is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
This medicine does not contain the ingredient NAD as implied by its name. Therefore, it may not work for claims related to NAD.
The website for this medicine contained claims specified in 'What action should consumers take?'. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
The website for this medicine contained claims specified in 'What action should consumers take?'. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor did not sufficiently address all the issues. The TGA cancelled this medicine and withdrew permission for further supply.
Grounds for cancellation
The medicine is not eligible for listing (paragraph 30(1A)(a) of the Act).
It appears to the Secretary that the presentation of the goods is unacceptable (paragraph 30(2)(aa) of the Act).
The goods do not conform to a standard applicable to the goods (paragraph 30(2)(e) of the Act).
It appears to the Secretary that the presentation of the goods is unacceptable (paragraph 30(2)(aa) of the Act).
The goods do not conform to a standard applicable to the goods (paragraph 30(2)(e) of the Act).
Additional information
This medicine was targeted to check its compliance in relation to claims about nicotinamide adenine dinucleotide (NAD, NAD+, NADH) or nicotinamide mononucleotide (NMN)